New hope for Tough-to-Treat blood cancer: MK-1045 enters human trials

NCT ID NCT05579132

Recruiting now Disease control Sponsor: MSD R&D (China) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests a new drug called MK-1045 (CN201) in people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking how well the drug works. About 203 participants, aged 2 and older, will receive the drug by IV infusion over several cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-1045 (also called CN201), a drug given by IV infusion
What this could lead to: If it works, this could provide a new treatment option for people with B-ALL whose cancer has returned or stopped responding to current therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not work as hoped or could cause serious side effects. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia precursor B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Hematology Hospital of Chinese Academy of Medical Sciences ( Site 0001)
RECRUITING

Tianjin, Tianjin Municipality, 301617, China
Henan Cancer Hospital-hematology department ( Site 0002)
RECRUITING

Zhengzhou, Henan, 450008, China
Southern Medical University Nanfang Hospital ( Site 0004)
RECRUITING

Guangzhou, Guangdong, 510515, China
The Affiliated Hospital of Xuzhou Medical University ( Site 0007)
ACTIVE_NOT_RECRUITING

Xuzhou, Jiangsu, 221002, China
The Children's Hospital of Zhejiang University School of Medicine ( Site 0009)
COMPLETED

Hangzhou, Zhejiang, 310003, China
The First Hospital of Harbin ( Site 0005)
RECRUITING

Harbin, Heilongjiang, 150010, China
The Second Affiliated Hospital of Third Military Medical University ( Site 0008)
RECRUITING

Chongqing, Chongqing Municipality, 400037, China
The Second Hospital of Hebei Medical University ( Site 0003)
RECRUITING

Shijiazhuang, Hebei, 050000, China
Tongji Hospital affiliated to Tongji Medical College of HUST ( Site 0006)
RECRUITING

Wuhan, Hubei, 430030, China
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology ( Site 0010)
RECRUITING

Wuhan, Hubei, 430022, China
West China Second University Hospital, Sichuan University ( Site 0011)
COMPLETED

Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.